[go: up one dir, main page]

WO1999019502A1 - Systeme de transfection pour transferer des acides nucleiques dans des cellules - Google Patents

Systeme de transfection pour transferer des acides nucleiques dans des cellules Download PDF

Info

Publication number
WO1999019502A1
WO1999019502A1 PCT/EP1998/006273 EP9806273W WO9919502A1 WO 1999019502 A1 WO1999019502 A1 WO 1999019502A1 EP 9806273 W EP9806273 W EP 9806273W WO 9919502 A1 WO9919502 A1 WO 9919502A1
Authority
WO
WIPO (PCT)
Prior art keywords
histone
transfection
dna
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/006273
Other languages
English (en)
Inventor
Prakash Chandra
Angelika Chandra
Ilhan Demirhan
Oliver Hasselmayer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Marion Roussel Deutschland GmbH
Aventis Pharma Deutschland GmbH
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP97117574A external-priority patent/EP0908521A1/fr
Priority claimed from EP98111001A external-priority patent/EP0967288A1/fr
Application filed by Hoechst Marion Roussel Deutschland GmbH, Aventis Pharma Deutschland GmbH, Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Deutschland GmbH
Priority to AU10290/99A priority Critical patent/AU1029099A/en
Publication of WO1999019502A1 publication Critical patent/WO1999019502A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Definitions

  • the invention relates to a new transfection system comprising a histone or a derivative thereof and a nucleic acid, the use of the new transfection system for any kind of nucleic acid transfection, especially the use of the new transfection system for gene therapy and for the preparation of pharmaceuticals.
  • the first barrier the cytoplasmic membrane
  • the first barrier can be traversed by many different methods (for reviews, see Keown et al., 1 990) like calcium phosphate precipitation (Loyter et al. , 1 982; Chen et al., 1 988), electroporation (Neumann et al., 1 982; Othani et al., 1989), liposome packaging of DNA (Fraley et al., 1 982; Nicolau et al.
  • polycations such as Polybrene (Kawai et al., 1 984), DEAE-dextran (Chandra et al., 1988; Demirhan et al., 1994; Graham et al., 1 973; McCutchan et al., 1 968; Choi et al., 1 988) or the use of proteins, which are taken up by the process of receptor-mediated endocytosis (Wagner et al., 1990; Zenke et al., 1990; Wu et al., 1 989; Wu et ai., 1991 ).
  • the method of receptor-mediated gene transfer is a specific approach, but it is limited by the presence and the number of receptors, which can be modulated in certain cases (Cotten et al., 1 990; Marceau et al., 1 990; Curiel et al., 1 992).
  • Histones may for example be used to condensate DNA as described in WO 96/20732 (p. 13, I. 21-32).
  • WO 96/20732 further describes the aspects which must be fulfilled by such a DNA condensate in order to speak of efficient transfection.
  • WO 96/20732 describes not the use of histones for transfection or transfection experiments carried out by using histone proteins.
  • Dubes G.G. et al. report a sensitizing effect of cells by basic proteins such as protamine and histone.
  • Cell "sensitization” is performed by incubating the cells solely with the basic proteins (1 ⁇ g/ml); then the cells are washed three times (p. 210-212).
  • Cells were then transfected with poliovirus RNA or polioviruses, and the infectivity was quantified by means of the plaques. It was found that the transfection rate was 0 4 - 10 5 higher with "sensitized cells". No incubation of histone with DNA or the use of histones in the transfection method itself is described.
  • histones are not used as DNA-carriers, they are only used as enhancers, additionals, cofactors or auxiliarys in combination with a known transfection method (variation of a known transfection method) or in addition to a known transfection reagent, e.g. as enhancer in the CaCI 2 method or as cofactor in receptor-mediated transfection.
  • a known transfection method variant of a known transfection method
  • a known transfection reagent e.g. as enhancer in the CaCI 2 method or as cofactor in receptor-mediated transfection.
  • Such an enhancer effect for histones is for example described in DE 196 16 645 A1.
  • DE 196 16 645 A1 an isolation method for nuclear proteins is described and the transfection activity of theses proteins including the histones H3 and H4 is investigated.
  • the transfection method used is a modification of the calcium phosphate/DNA coprecipitation method, since it is disclosed that calcium must be added both to the complex formation buffer (col. 5, I. 19-22) and to the transfection medium (col. 3, I. 49-56; col. 5, I. 30-33).
  • the transfection method described in WO 96/14424 is also a variation of the calcium phosphate/DNA coprecipitation method which is used as the initial method (p. 3, I. 15-21 ).
  • the variation comprises adding the histones (especially H2A) to calcium phosphate/DNA precipitates which have already formed (p. 2, I. 25-27; p_. 3, I. 30-33, table 1 ; p. 15, claim 9).
  • H2A histones
  • Ca 2+ in the form of calcium chloride or calcium nitrate is also an essential constituent of the described transfection kit (p. 3, I. 2-9; p. 15, claim 8).
  • histones alone lead to no transfection i.e. histones are inactive as transfection reagent (p. 4, I. 5-7).
  • DD 256 148 A1 in addition describes a variation of the well-known Ca 2+ transfection method by using calcium phosphate and as auxiliary component histone proteins.
  • DD 256 148 A1 futhermore confirms the teaching of WO 96/14424 that histones are unable to transfect cells in the absence of calcium phosphate (p. 6, example 2, I. 6- 10).
  • histones stimulate transfection only if HMG-1 proteins are present.
  • the transfection system consists of the DNA to be transferred and a transferrin-polylysine conjugate (p. 4255, left-hand col., 2nd paragraph, section (ii); "Materials and Methods", right- hand col., section "Cell culture and transfection”).
  • the complex formation of the transferrin-polylysine conjugate is a precondition for the stimulating effect of
  • Obaru K. et al. Human Gene Therapy 7, 2203-2208, (1996) used the DEAE- dextran method for transfection (abstract, p. 2203, I. 6-7; p. 2204-2205 "transient expression assay") of an expression vector which comprises the LTR sequence of HIV-I and a sequence that encodes tat protein (p. 2204, Figure 1 ).
  • Feigner P.L. (Adv. Drug Delivery Rev. 5, 163-187, (1990)) reviews the current transfection methods and possible ways of increasing their efficiency. For example, the use of cationic lipids for increasing transfection efficiency is proposed. In this connection an enhancing effect of histones and protamines is diclosed (p. 166, 2nd paragraph, I. 2-4).
  • transfection system which transfection comprises the DNA to be transfected (in the form of a plasmid), anionic liposomes and cationic DNA-binding protein (abstract (p. 47); introduction (p. 47, right-hand col., I. 3, 4 in the 2nd paragraph); (p. 48, left-hand col., 1 st paragraph)).
  • the cationic DNA-binding protein consists of a construct which comprises the nuclear localization sequence of the SV40 T antigen and of histone H1.
  • the present invention aims to provide a universal transfection system that can be used to bring a nucleic acid into a prokaryotic and/or an eukaryotic cell, in particular into the nuclei of an eukaryotic target cell in a simple and effective manner.
  • a transfection system that comprises 1 . a basic protein that tends to aggregate with a nucleic acid and which has a nuclear localization signal (NLS) responsible for targeting the protein into the nucleus and 2. a nucleic acid and 3. optionally additional compounds.
  • NLS nuclear localization signal
  • Transfection means that a nucleic acid, such as for example DNA is brought into a cell
  • transfection means that a nucleic acid is brought into an eukaryotic cell and that the nucleic acid brought into a cell is functionally active.
  • Transfection system means a system that comprises the nucleic acid that should be transferred/transported.
  • the transfection system comprises a transfecting reagent that can be used to transfer the nucleic acid.
  • the transfecting reagent is preferably a basic protein that tends to aggregate with the nucleic acid to be transferred and which has a nuclear localization signal (NLS) responsible for targeting the protein into the nucleus.
  • the transfecting reagent is preferably a histone protein or a derivative thereof, most preferably a histone H3 and/or a histone H4 or a derivative thereof.
  • One of the most favorable embodiments of the invention relates to a transfection system that comprises 1 . a histone protein or a derivative thereof and 2. a nucleic acid and 3. optionally additonal compounds.
  • the transfection system according to the invention contains non of the known transfection reagents, such as for example high Ca 2+ concentrations (like in the CaCI 2 method), liposomes, lipofectins, receptors and/or DEAE- dextran in a concentration known to be used in these transfection methods.
  • non of the known transfection reagents such as for example high Ca 2+ concentrations (like in the CaCI 2 method), liposomes, lipofectins, receptors and/or DEAE- dextran in a concentration known to be used in these transfection methods.
  • Histones are basic proteins which are components of the chromatin structures naturally occuring in most of the nuclei of eukaryotic cells. Histones are characterized by having an unusually high amount of basic amino acids (about 20 to 30 %) and a relative molecular weight of about 1 1 .000 to 24.000 Da (e.g. Benjamin Lewin ( 1983) "Genes III", John Wiley & Sons, Inc. New York, p. 519-558).
  • histones 2A, 2B, 3 and 4 form a histone octamer which interacts directly with DNA to form the first level of particles in the chromatin
  • histone 1 H1
  • the histones H3 and H4 are the most Arginine-rich histones.
  • bovine histone H3 contains about 13 % Arginin, 10 % Lysin and has a relative molecular weight of about 1 5,3 kDa.
  • the bovine histone H4 contains about 14 % Arginin, 1 1 % Lysin and has a relative molecular weight of about 1 1 ,2 to_ - 1 1 ,3 kDa.
  • the histones H3 and H4 are among the most conserved proteins known in evolution. For example the sequences of the 102 amino acid sequence of bovine H4 differs only in two amino acids from that of the pea and the sequences of the 135 amino acid sequence of bovine H3 differs in 4 amino acids from that of the pea (Lexikon der Biochemie und Molekularbiologie ( 1991 ) Herder Verlag, Freiburg). Histone 3 and histone 4 are small positively charged proteins which can bind _ nucleic acids by ionic interactions. In addition H3 and H4 have nuclear location signal (NLS) sequences.
  • NLS nuclear location signal
  • the transfection system comprises histone 3 (H3) and/or a derivative thereof and/or histone 4 (H4) and/or a derivative thereof.
  • the invention comprises a mixture of histones or derivatives thereof preferably of H3 and H4 and optionally other compounds.
  • Derivatives of histones comprise any histones, in particular naturally occuring histones that have been modified or altered in any way with the provise that their specific ability to aggregate with nucleic acids and translocate them into the nuclei of cells is maintained. Modifications are for example deletion and/or addition of one or more amino acids from/to the aminoterminal and/or from/to the carboxyterminal end of the histone protein and/or from/to somewhere in the middle of the amino acid sequence. Further examples for alterations are amino acid changes or amino acid substitutions respectively within the naturally occuring amino acid sequence of a histone and/or modifications of amino acids, e.g. acetylation (e.g.
  • ⁇ -aminogroup of lysine residues ⁇ -aminogroup of lysine residues
  • ADP-ribolysation e.g. glutamine residues
  • methylation and/or phosphorylation e.g. hydroxy group.? -. of serine and/or threonine residues.
  • the invention also comprises a method of making the transfection system.
  • the transfection system can be made by mixing a histone with a nucleic acid. Upon mixing the histone may be incubated with the nucleic acid. In a special embodiment the incubation time is about 5 to 60 minutes, preferably 10 to 30 minutes, most preferably about 15 minutes.
  • making the transfection system respectively e.g. a histone protein that has been isolated and/or a recombinant histone protein ("histone protein" and "histone" are used in the same sense) can be used.
  • the histone can for example be obtained by isolation from any kind of cells and/or cell lines, any kind of animal tissue, preferably thymus or from human/animal umbilical cords, human/animal transplantation waste product, human/animal biopsy-material, human/animal tumor tissue (e.g. material which has been removed by surgery) and/or human/animal placenta.
  • a method for the isolation of histone protein from tissue and/or cells is for example described in E.W. Johns, Biochem. J. 92, 55-59 ( 1964) .
  • a recombinant histone protein can be obtained by expression of histone- encoding DNA, e.g. a gene in prokaryotic and/or eukaryotic cells.
  • human histone protein can be obtained by cloning a DNA that encodes human H3 (for example a DNA encoding for the amino acid sequence in table 7) and/or a DNA that encodes human H4 (for example a DNA encoding for the amino acid sequence in table 5) in an appropiate (expression-) vector.
  • Such expression vector can than be used to express the histone in a suitable h ⁇ st cell.
  • Histones can also be obtained from transgenic animals which (over)-express a particular histone-transgene. Such histone-transgene would e.g. comprise a histone encoding DNA sequence under the control of a suitable promoter. . _
  • the histone-encoding DNA can e.g. be a gene or a cDNA or a part thereof.
  • the histone-encoding DNA may be a cDNA that encodes for a protein with the amino acid sequence SEQ ID NO. : 1 , SEQ ID NO.: 2, SEQ ID NO. : 3 or SEQ ID NO. : 4.
  • Sequences of histone encoding DNA can be obtained from genetic sequence databases such as for example from the NCBI (National Center for Biotechnology Information), EMBL (European Molecular Biology Laboratory) - and/or the Internet for example under http://www.ncbi.nlm.nih.gov.Baxevani/HISTONES/table.html.
  • H3 and H4 isolated from calf thymus
  • H4 isolated from calf thymus
  • the histones from Fluka are prepared by a modified preparation process according to E.W. Johns, Biochem. J. 92, 55-59 (1964).
  • the histone protein can be from any kind of animal and/or eukaryotic microorganism and/or plant , e.g. from a vertebrate and/or a mammalian such as for example rodent, primate, sheep, goat, dog, cow, pig, bird and/or amphibian, reptile. This is of particular interest, since for example H3 and H4 are highly conserved between different species.
  • the consensus sequence for H3 is given in table 6.
  • the amino acid sequence of human H3 (table7) differs only in 6 positons (5 within the sequence, 1 at the carboxy terminal end and 1 insertion at the carboxy terminal end) from the consensus sequence.
  • the consensus sequence for H4 is given in table 4.
  • the amino acid sequence of human H4 (table 5) differs only in 3 amino acids from the consensus sequence.
  • the nucleic acid which should be transferred can for example be a DNA, RNA, oligonucleotide or derivative thereof.
  • a derivative is for example a nucleic acid- in which the phosphodiester internucleoside linkage, the sugar unit, the nucleobase and/or the sugar-phosphate backbone has been modified and/or replaced.
  • Derivatives include also nucleic acid salts, in particular a physiological tolerated salt of a nucleic acid.
  • the nucleic acid can for example be isolated and/or synthesized by chemical and/or enzymatical methods.
  • the nucleic acid may have any kind of length.
  • the nucleic acid may be relatively short, for example it may comprise only 10 or less, 20, 30, 40, 50 or 100 nucleotides.
  • the nucleic acid may comprise 1000, 10000, 100000, 1000000 or more nucleotides.
  • the nucleic acid may be a chromosome.
  • the nucleic acid may comprise for example any kind of gene, derivatives and/or parts thereof, any kind of cDNA, derivatives and/or parts thereof.
  • the nucleic acid can be linear and/or circular (e.g. plasmid, cosmid, artificial chromosome).
  • the nucleic acid may contain a sequence that encodes for a protein, e.g. a soluble and/or unsoluble and/or membrane bound protein.
  • the nucleic acid may contain a sequence that encodes for example for a peptide, enzyme, receptor, cell-adhesion protein, immunomodulator, growth factor, tumorsupressor, regulator protein as e.g. transcriptionfactor, co-factor and/or trans-activating factor.
  • the nucleic acid contains a sequence that encodes for a protein or a peptide which is involved in the formation or the development of a disease.
  • the nucleic acid may function, in particular if the nucleic acid is a RNA or contains a sequence that encodes a RNA and/or the nucleic acid is an oligonucleotide or a modified derivative thereof as antisense oligonucleotide, as triplex-forming oligonucleotide and/ ⁇ r - as ribozyme (e.g hammerhead-ribozyme).
  • the nucleic acid should be able to bind to a target nucleic acid.
  • a functionally active nucleic acid means for example that if the nucleic acid e.g. comprises a protein encoding sequence the protein can be expressed (transcribed and/or translated) or e.g. if the nucleic acid comprises an oligonucleotide or a antisense RNA can bind to a target sequence.
  • the nucleic acid source may be any human and or non-human animal, plant, microorganism such as e.g. bacteria, fungi (e.g. yeast), virus, retrovirus.
  • the nucleic acid contains a DNA sequence that encodes among others for the enzyme Chloramphenicol-Acetyl- Transferase (CAT). In another special embodiment of the invention the nucleic acid contains a DNA sequence that encodes beyond others for the HIV-1 protein tat.
  • CAT Chloramphenicol-Acetyl- Transferase
  • genes/cDNAs/coding sequences which could be (part of) the nucleic acid are immun-modulating genes such as those of cytokines like GM-CSF, IFN- ⁇ , IL-2, alloantigen genes such as HLA-B7, "suicide" genes such as HSV-thymidine kinase, co-stimmulatory genes such as B7-1 , tumor-associated antigenes, such as MART-1 , tumor-suppressor genes such as p53, antisense genes that target oncogenes, antigrowth-factor genes, drug resistance genes.
  • immun-modulating genes such as those of cytokines like GM-CSF, IFN- ⁇ , IL-2, alloantigen genes such as HLA-B7, "suicide” genes such as HSV-thymidine kinase, co-stimmulatory genes such as B7-1 , tumor-associated antigenes, such as MART-1 , tumor-suppressor genes
  • the nucleic acid may comprise the sequences of one or more gene-regulatory sequences for the controlled expression, e.g. natural and/or synthetic promotors and/or enhancers. Promotors may be constiutive and/or inducible.
  • the nucleic acid can comprise a basal promotor, a viral promotor, a promotor which is activated upon metabolic stimulation or upon treatment with a specific drug (e.g. tetracyclin), a cell-cycle specific promotor, a cell-type specific - - promotor and/or a chimeric promotor.
  • the nucleic acid comprises the adenovirus major late promoter.
  • the nucleic acid comprises an inducible promoter which is activated upon stimulation with a specific trans-activating factor.
  • the inducible promotor is the HIV-1 long terminal repeat (LTR). This promotor is stimulated by the trans-activating factor tat which is specific for a particular cell type since its expression is restricted to HIV-infected cells.
  • the transfection system may comprise different ratios of nucleic acid and histone.
  • the transfection system may comprise a nucleic acid to histone ratio of about 1 to 5, 1 to 4,5, 1 to 4, 1 to 3,5, 1 to 3, 1 to 2,5, 1 to 2, 1 to 1 ,5, 1 to 1 or less.
  • the transfection system may comprise a nucleic acid to histone ratio of about 1 to 5,5, 1 to 6, 1 to 6,5, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 100 or more.
  • the nucleic acid to histone ratio may be 1 ,5 to 1 , 2 to 1 , 2,5 to 1 , 3 to 1 , 3,5 to 1 , 4 to 1 , 5 to 1 , 10 to 1 , 100 to 1 or more.
  • the transfection system comprises a nucleic acid to histone ratio of 1 to 5.
  • “Ratio" means the mass to mass ratio of histone protein and nucleic acid.
  • the nucleic acid comprises one or more plasmids.
  • plasmids pCV1 comprises tat gene and SV40 promotor
  • pC1 5CAT comprises HIV-1 LTR and CAT
  • the plasmids pCV1 (figure 1 ) and pC1 5CAT (figure 2) are described in Chandra et al. (1 988) FEBS letters, Vol. 236, 282-286.
  • the transfection system may comprise additional compounds. These _ - compounds are for example proteins, peptides, amino acids, chemical substances. Histones prepared from tissue and/or cells and/or cell nuclei may for example comprise additional compounds such as for example cofactors. If histones that have been isolated from tissue were used in the transfection system, the transfection system may comprise additional compounds assocciated with the histone protein and/or contained in the histone fraction such as for example in Johns fraction f3 and/or f2a.
  • the transfection system can be universally applied, e.g. whenever a nucleic . acids should be brought into (the nuclei of) a cell or whenever a genetically engineered cell (recombinant cell, transgenic cell) should be provided.
  • the transfection System can e. g. be used in vitro and /or in vivo.
  • Cells are preferably any types of eukaryotic cells and/or cell lines, cells of tissues and/or tissue cultures and/or cells of animals and/or plants and or prokaryotic cells.
  • Non-limiting examples are endothel cells, muscle cells, hamopoetic cells, steam cells, cells belonging to the immuno system (e.g. T- cells, B-cells, lymphoctes, macrophages), glia cells, tumor cells and/or derivatives thereof.
  • the transfection system is used to bring a nucleic acid into the nuclei of a Jurkat cell.
  • the transfection time (incubation time of transfection system with the cell) is about 10 minutes (min) or less, 30 min, 45 min, 60 min, 1 ,5 hours (hrs), 2 hrs, 2,5 hrs, 3 hrs, 4 hrs, 5 hrs, 6 hrs, 7 hrs, 8 hrs, 9 hrs, 10 hrs, 1 1 hrs, 12 hrs, 14 hrs, 1 6 hrs, 1 8 hrs, 20 hrs, 24 hrs.
  • the transfection time is the time the transfection system is incubated with a cell.
  • the invention also relates to the use of the new transfection system.
  • the new transfection system can be used to transfer a nucleic acid into a cell. . -
  • the invention also relates to the use of a histone to transfer a nucleic acid into a cell.
  • the invention also relates to the use of a histone protein in a method of making the transfection system.
  • the invention also relates to the use of a histone protein in the transfection system.
  • the invention also relates to the use of a histone for making a transgenic cell.
  • the invention relates to the use of the transfection system for making a transgenic cell.
  • a transgenic cell is a cell, into which a nucleic acid has been . introduced.
  • the invention rates to a method of making a transgenic cell by using a histone.
  • the invention further relates to a method of making a transgenic cell by using the transfection system.
  • a method of making a transgenic cell by using the transfection system is a two step process:
  • the transfection system is made prior to the transfection process by mixing and optionally incubating a histone and a nucleic acid and
  • the transfection system is than incubated with a cell, optionally for a particular time period (incubation time).
  • the method of making a transgenic cell by using the transfection system is characterized in that upon incubating the transfection system with a cell, the transfection system is transferred into the cell, e.g. into the nucleus of the cell.
  • the method of making the transgenic cell might be applied e.g. in gene therapy, in particular in somatic gene therapy.
  • the invention further relates to a transgenic cell made by transferring a nucleic acid into a cell by using a histone and/or the transfection system. Therefore, the transfection system can for example be used as tool in molecular biology.
  • the transfection system can for example be used in diagnosis and for the preparation of diagnostic tests. It can furthermore be used to prepare cells for the use in screening assays, e.g. for the screening of new protein and/or nucleic acid targets and/or the screening of highly specific new drugs.
  • the transfection system or a histone protein or a pharmaceutical composition thereof can be used for DNA-vaccination and/or for immune therapy.
  • the transfection system or histone protein can be used in gene therapy, in particular for somatic gene therapy and/or for the preparation a pharmaceutical composition that can be used in gene therapy, in particular for somatic gene therapy.
  • a pharmaceutical composition should comprise an effective amount of the transfection system or histone protein.
  • Such pharmaceutical composition can be used for ex vivo and/or in vivo application.
  • the pharmaceutical composition comprises the transfection system, it may directly be used. If on the other hand, the pharmaceutical composition comprises only histone protein, the pharmaceutical composition must be mixed and optionally incubated with a nucleic acid prior to its used.
  • hemapoetic stem cells e.g. from bone marrow
  • transfected stem cells may for example be enabled to target specific cells, e.g. tumor cells and optionally deliver e.g. nucleic acids to those cells.
  • a specific nucleic acid e.g. with a promotor which is acivated only in a specific cell type and/or at a specific point of development and/or differentiation and/or cell cycle
  • the transfection system and/or a pharmaceutical composition thereof can for example be injected into particular tissue. This is possible because the transfection system is taken up by a cell very efficiently. This method may
  • a pharmaceutical composition can be prepared in a manner known per se (e.g. Remingtons Pharmaceutical Sciences, Mack Publ. Co., Easton, PA), with pharmaceutically inert inorganic and/or organic excipients being used. Lactose, corn starch and/or derivatives thereof, talc, stearic acid and/or its salts, etc. can, for example, be used for preparing pills, tablets, coated tablets and hard gelatin capsules. Examples of excipients for soft gelatin capsules and/or suppositories are fats, waxes, semisolid and liquid polyols, natural and/or hardened oils, etc.
  • Suitable excipients for preparing solutions and/or syrups are water, sucrose, invert sugar, glucose, polyols, etc.
  • Suitable excipients for preparing injection solutions are water, alcohols, glycerol, polyols, vegetable oils, etc.
  • Suitable excipients for microcapsules, implants and/or rods are mixed polymers of glycolic acid and lactic acid.
  • a pharmaceutical composition can also comprise additives, such as fillers, extenders, disintegrants, binders, lubricants, wetting agents, stabilizing agents, emulsifiers, preservatives, sweeteners, dyes, flavorings or aromatizing agents, thickeners, diluents or buffering substances, and, in addition, solvents and/or solubilizing agents and/or agents for achieving a slow release effect, and also salts for altering the osmotic pressure, coating agents and/or antioxidants.
  • additives such as fillers, extenders, disintegrants, binders, lubricants, wetting agents, stabilizing agents, emulsifiers, preservatives, sweeteners, dyes, flavorings or aromatizing agents, thickeners, diluents or buffering substances, and, in addition, solvents and/or solubilizing agents and/or agents for achieving a slow release effect, and also salts for altering the osmotic pressure, coating agents
  • a pharmaceutical composition may comprise the transfection system.
  • the pharmaceutical composition may comprise histone H3 and/or histone H4.
  • a pharmaceutical composition can be made by mixing the transfection system or a histone with the other components contained in the composition.
  • the dose of the pharmaceutical composition can vary within wide limits and is to be adjusted to the individual circumstances in each individual case.
  • the transfection system or the pharmaceutical composition may be an aerosol that can be inhaled, it may in a liquid that can be injected or drunken or it may be in a solid form for oral uptake.
  • the transfection system or the pharmaceutical composition can be used for the diagnosis, the prevention and/or the treatment of diseases, for example different kinds of cancer such as for example melanoma, carcinoma, lymphoma, basalioma, sarkoma, adenoma, neuroblastoma, glioma, teratoma, haemoblastoma in different kinds of tissues like for example head, brain, neck, skin, breast, stomache, kidney, bone, hepatic system, muscle, lung, prostate and different kinds of infections such as for example infections with different kinds of Influenza-virus, HIV (human immunodeficiency virus), HSV (herpes simplex virus), CMV (cytomegalo virus), HBV (hepatitis B-virus), HCV (hepatitis C-virus) and other types of hepatitis viruses, helicobacter pylori, malaria, cholera, typhus, grain and different kinds of genetic diseases such as for example cystic fibrosis, thalassaemia, cardiovascular
  • Lipofection reagents have been studied in comparison to DEAE-dextrarj _ gene delivery system.
  • DOTAP, Dosper and lipofectin have shown lower transfection efficiency.
  • lipofectamine had a 2, 5-fold better efficiency compared to that of DEAE-dextran. This could be due to it's stronger cationic character leading to a better condensation of DNA.
  • This invention provides a novel and highly efficient DNA carrier system using the natural DNA-binding proteins, histones 3 and 4. Both proteins have nuclear location signal sequences which are responsible for their rapid accumulation in the cell nucleus. This transfection method (histonefection) is simple and not targeted to specific cell surface receptors.
  • HIV-1 LTR transactivation of HIV-1 LTR by the transactivator protein tat, both expressed in Jurkat cells was determined. HIV-1 LTR was hybridized to the gene of CAT which was used as reporter gene. In the experiments the level of expression of CAT was a direct measure of transactivation.
  • histonefection resulted in a 7-fold increase of CAT expression.
  • the maximum transfection efficiency of histones is dependent on concentration (DNA : histone ratio) and the incubation time.
  • concentration DNA : histone ratio
  • gel shift assay gel shift assay
  • This invention provides a simple histone-mediated gene delivery system that can be used to translocate foreign genes into target cells.
  • the nuclear location and natural DNA-binding capability of histones make them ideal for delivering DNA into the cell nucleus.
  • the simple construction of the histone-based carrier system means less variables need to be controlled, and there is a greater reliability in this method as compared with systems, which used receptor-mediated endocytose.
  • In order to construct a natural ligand- . - polylysine complex with transferrin-receptor was used for transfection (Wagner et al., 1991 ).
  • the renunciation of natural ligand to cell surface receptors by the use of unmodified histones in this method is potentially applicable to eukaryotic cells without specific surface receptors.
  • the transfection with histones is more efficient than all the other tested transfection reagents.
  • the histones mediates a 7-fold increase in transfection efficiency and only lipofectamine as one of tested lipofection reagents mediates a 2, 5-fold increase.
  • the present invention provides a powerful transfection system which is very efficient, not time and material consuming, which is easy to perform and can be applied universally.
  • the transfection system is not toxic for cells and/or animals and/or humans and/or plants since histones are cellular proteins. Due to the simple method of transfection the cells are not stressed by the procedure.
  • Jurkat cells co-transfected with plasmids carrying that gene (HIV-1 ) and LTR sequence (HIV-1 ) hybridized to the reporter gene CAT are able to express CAT protein.
  • the level of CAT expression is dependent on the transfection efficiency and the transgene expression of the tat protein. Different transfection systems were compared with respect to their transfection efficiency under optimal conditions of DNA : reagent ratio and the time of incubation.
  • a first step the different gene delivery systems (transfection systems) were compared at various DNA : reagent ratios.
  • table 2 the level of CAT expression at different DNA : reagent ratios employing various gene- delivery systems are shown.
  • the optimal concentration of these reagents with fixed amount of plasmid DNA that gave the best transfection efficiency was determined in each case.
  • the varying amounts of plasmid DNA used in different lipofection experiments are used according to the instruction manuals supplied by the companies.
  • Lipofectin and Lipofectamine have the optimal effect at a DNA to transfection reagent ratio of 20:35, DOTAP (50: 120) and Dosper (40: 100) have similar requirements for their optimal activity, and histone 3 (40:200) and histone 4 (40:200) exhibit a close relationship in their DNA requirement for the maximum transgene expression. If the different transfection methods are compared at their optimal DNA : reagent ratio, the highest transgene expression is catalyzed by histonefection (transfection by histones). Except for Lipofectamine, the transfection efficiency of all the lipofection reagents was inferior to that of DEAE-Dextran.
  • the transfection period for optimal transgene expression was determined.
  • the incubation period over which the DNA-reagent complex (transfection system) must be in contact with the cell to exert its optimal effect is dependent on several factors. The important ones are:
  • reagent i) the chemical nature of the reagent (carrier); ii) the cell type; and iii) the concentration of DNA and the carrier.
  • the level of CAT expression at different periods of incubation for lipofectin, lipofectamin, DOTAP, Dosper, histone 3 and histone 4 was determined (table 3).
  • lipofectin, DOTAP and Dosper exhibit a similar behaviour with a transfection activity lower than that of DEAE-Dextran.
  • The. __ optimal period of incubation for lipofectin is between 3 to 5 h, whereas for DOTAP and Dosper between 7 and 9 hours.
  • Lipofectamine which has a higher transfection potential than DEAE-Dextran shows the highest gene expression in the first three hours; longer incubation periods with lipofectamine lead to a sharp decrease in the expression of CAT activity.
  • the antibody is murine monoclonal antibody (IgG) which binds specifically to an antigen determinant, present on all five histone proteins (anti-histone, pan).
  • the histone 3 and histone 4 lose their transfection potential by increasing amounts of antibodies.
  • the inhibitory effect of histone IgG on histone-mediated CAT expression is concentration dependent.
  • histones were preincubated with histone IgG and then mixed with DNA and added this transfection cocktail to the cells.
  • histone IgG histone 3 and histone 4 mediated condensation of plasmid DNA was investigated in gel-retardation assay.
  • the mass ratios between plasmid DNA and histone were same as in the above experiments without histone IgG. Varying amounts of histone were preincubated with histone IgG (10 / y g/ml) and then added to the plasmid DNA. Contrary to what was expected, histone IgG intensifies the mobility retardation effect of both histones.
  • the protection of plasmid DNA against cellular nuclease is important for the functional activity of transgenic DNA, therefore the effect of DNase and _ _ restriction enzymes on the degradation of plasmid DNA alone and the DNA : histone complex (1 :5) was studied.
  • the probes were incubated with DNase alone, or in combination with restriction enzymes and separated on gels.
  • Lane 8 depicts the separation pattern of plasmid DNA treated with restriction enzymes only.
  • the gel pattern of DNA treated with Dnase and restriction enzymes alone, or in combination are qualitatively the same. However, minor differences in the intensivity of some bands were seen.
  • This feature of the transfection system is an important aspect for the functional activity of the transferred nucleic acid.
  • histone-based gene carrier system (transfection system) has several advantages:
  • Histone 1 and histone H2A showed no transfection potential in this system when used as transfection reagent in the transfection system (data not shown).
  • the CAT expression in the presence of polylysine was 338 _+_ 42 pg/10 /yg protein whereas, the control value without any addition, i.e. plasmid DNA alone, was, 310 _+_ 51 pg/10 yg protein. Based on CAT expression, the transfection potential of histones 3 and 4 is approximately 200 times that of control value where plasmids were used alone.
  • Figure 1 Construction of the plasmid pCV1 with AdMLP (adenovirus major late promotor) and the cDNA of the tat gene.
  • Figure 2 Plasmid pC1 5CAT with SV40 promotor, HIV-1 LTR (C1 5) and CAT gene (CAT).
  • DNA:reagent ratios a) Lipofectin; b) Lipofectamine; c) DOTAP; d) Dosper; e) histone 3 and f) histone 4.
  • Figure 4 Transfection potential of different gene-delivery systems at various transfection periods: a) Lipofectin; b) Lipofectamine; c) DOTAP; d) Dosper; e) histone 3 and f) histone 4.
  • the mass ratios for DNA:reagent complexes were based on the maximum activity for each reagent obtained in experiments shown in Fig. 3.
  • Figure 5 The diagram shows a comparison of the different transfection methods (1 to 7) with respect to the best incubation time for transfection.
  • the best incubation time for each transfection method has been determined in separate experiments (results in table 3). For these experiments in each case the best ratio of DNA:reagent has been used.
  • Figure 6 Effect of histone IgG on histone 3 (Fig. 3a) and histone 4 (Fig. 3b) mediated transgene expression in Jurkat cells.
  • Figure 7 Electrophoretic mobility of plasmid DNA in the presence of various amounts of histone 3 (Fig. 4a) and histone 4 (Fig. 4b).
  • Figure 8 Electrophoretic mobility of histone-DNA complexes (histone 3, Fig. 5a; histone 4, Fig. 5b) in the presence of histone IgG (10 / g/ml).
  • Figure 9 Effect of histones on the nucleolytic degradation of plasmid DNA measured by gel electrophoresis.
  • the culture medium (RPMI 1 640 with 10% fetal calf serum and 1 % penicillin and streptomycin), the wash medium (RPMI) and fetal calf serum (FCS) were supplied by GIBCO BRL, Eggenstein.
  • Jurkat. cells (clone E 6-1 , Weiss et al. 1985) an immortal cell line derived from T-lymphocytes were cultured in culture
  • C-acetyl-CoA (4 mCi/mmol) was obtained from NEN/Dupont (Dreieich). All other reagents were analytic-grade of high purity obtained from Boehringer Mannheim, Mannheim (DOTAP and Dosper), FLUKA, Neu-Ulm (poly-lysine and histones 3 and 4), GIBCO BRL (lipofectin and lipofectamine) or from Sigma, Deisenhofen (DEAE-dextran).
  • the tat gene (clone 1 ) was cloned by way of cDNA-cloning, using poly (A)- selected RNA from HIV-1 (BH 10) infected cells (Arya et al., 1985; Chandra et al., 1988).
  • the plasmid pCV1 (figure 1 ) was obtained by inserting viral cDNA containing the tat gene (clone 1 ) into the mammalian expression vector pCV which contains duplicated SV40 origins of replication (ori), adenovirus major late promotor, splice sites from adenovirus and mouse immunoglobulin genes, mouse dihydrofolate reductase cDNA, and SV40 polyadenylation signal.
  • the HIV-1 LTR-CAT construct was obtained by inserting clone 15 DNA into pSVO- CAT at the Hind III site (Arya et al., 1985; Arya et al., 1986) and the resulting plasmid was termed pC15CAT (figure 2).
  • Example 1 Comparable transfection experiments.
  • DOTAP N-[1 -(2,3-dioleoyloxy)-propyl]-N,N,N- trimethylammonium methylsulfate
  • the Jurkat cells were washed twice with serum-free medium and resuspended in 4 1 5 ml up to 4,65 ml culture medium.
  • the plasmids (5 ⁇ g of each plasmid per 1 x10 6 cells) were diluted in 250 ⁇ l HEPES (20 mM).
  • DOTAP was solved in concentrations between 5 - 30 ⁇ g/ml in 100 /I to 600 ⁇ l HEPES buffer and mixed gently with the plasmid solution.
  • the mixture was incubated for 1 5 min. at room temperature.
  • the DNA-DOTAP complex was added to the resuspended cells and incubated between 1 and 24 hrs. Then the medium was substituted with fresh RPMI medium and the cells were cultured for 72 hrs at 37°C and 5 % CO 2 .
  • FCS and 4,5 ml culture medium were added to the cells and the cells were incubated for 24 hrs with 5 % CO 2 . Cells were centrifugated and resuspended in 5 ml fresh culture medium and then incubated for further 48 hrs under same conditions.
  • Lipofectin (a 1 : 1 [w/w] mixture of DOTAP (N-[1 -(2,3-dioleoyloxy)-propylJ- N,N,N-trimethylammonium chloride (DOTMA) and dioleoyl phosphotidylethanolamine (DOPE)) or lipofectamine ( a 3: 1 mixture of 2,3-dioleoyloxy-N-2-spermine carboxamidoethyl-N,N-dimethyl-1- propa ⁇ ammoniumtriflouroacetat (DOSPA) and dioleoyl phosphotidylethanolamine) were used in concentrations between 5 and 45 ⁇ g/ml.
  • DOTAP N-[1 -(2,3-dioleoyloxy)-propylJ- N,N,N-trimethylammonium chloride
  • DOPE dioleoyl phosphotidylethanolamine
  • DOSPA 2,3-d
  • CAT assays 30 ⁇ of the cell extract were mixed with 20 ⁇ l of 100 mM Tris-HCI (pH 7.8) in a 6 ml glass scintillation vial. The vial was transferred to a water bath set to 37°C and 200 ⁇ l of freshly prepared CAT-reaction mixture
  • histone:DNA The optimal mass ratio of histone to DNA (histone:DNA) was detected in a gel retardation assay.
  • the samples with a ratio from 1 : 1 up to 5: 1 were electrophoresed on a 1 % agarose gel.
  • a gel retardation assay the migration of plasmid DNA is increasingly retarded as concentrations of the histones increased.
  • 10 ⁇ l loading buffer 50 % 1xTE, 50 % glycerol and 0,05 % of brome phenolblue and xylene xyanol
  • Jurkat cells were transfected with histone 3/plasmids pCV1 and pC15CAT (1 :1 ), histone 4/plasmids (pCV1 + pC15CAT, 1 : 1 ) and polylysine/plasmids at - various protein:DNA ratios. For both histones, the optimal (histone 4) or nearly the optimal (histone 3) protein-DNA binding ratio also gave the best reporter gene expression in Jurkat cells. Experiments with polylysine leaded to no transfection in Jurkat cells.
  • Example 6 Inhibition of transfection (histonefection) by monoclonal anti- histone antibodies.
  • Histones H3 and/or H4 in HBS were incubated with anti-histone antibodies (mouse-lgG 1 against the pan- epitope, available from Boehringer Mannheim, No. 1 471 , 519, Biochemicals Catalog 1995) (concentration of anti-histone antibodies 0-10 ⁇ g/ml) for 1 hour at 37°C. The rest of the procedure was performed as described in example 1 (incubation with plasmids, transfection) and example 3 (gel shift assay).
  • Example 7 Preparation of histones from animal tissue (E.W. Johns (1964) Biochem. J. 92, 55-59).
  • Tissue from calf thymus is homogenized in 0.9 % NaCI-solution and centrifuged at 1 100 g.
  • the pellet is washed five times with 0.9 % NaCI.
  • the pellet is homogenized with 5 % perchloric acid and zentrifuged at 1 100 g two times.
  • the pellet is suspended in ethanol and incubated at 4°C for 18 hours.
  • the suspension is centrifuged (1 100 g) and the pellet is washed with ethanol twice.
  • the supernatants from ethanol extractions are collected, pooled and centrifuged at 2500 g.
  • the supernatant is mixed with aceton (5 x volume) and then with concentrated HCI.
  • the pellet is washed with aceton and dissolved in H 2 O. Then ethanol (end concentration 80%) and HCI (end concentration 0.25 N) are added and the solution is dialysed 18 hours against ethanol. Then the solution is again dialysed under the same conditions for 4 hours.
  • the pellet (f3) is washed once with ethanol and three times with aceton and dried in vakuum. The supernatant is mixed with aceton (3 x volume) and the pellet (f2a) is washed twice with aceton and dried in vakuum.
  • Table 4 Consensus sequence of histone 4 (H4) amino acid sequence (Accession No.: X00038) (SEQ ID NO.: 1 ).
  • H4 Humane histone 4 (Accession No.: P02304HSEQ ID NO.: 2)
  • Fig. 6a Inhibition of histonefection with histone H3 by histone-lgG
  • Fig. 6b Inhibition of histonefection with histone H4 by histone-lgG

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un système de transfection comprenant des histones ou leurs dérivés et l'acide nucléique à introduire dans des cellules. L'invention concerne en outre l'utilisation du système de transfection pour tout type de transfection d'acide nucléique, notamment l'utilisation du système de transfection en thérapie génique et dans la préparation de médicaments.
PCT/EP1998/006273 1997-10-10 1998-10-02 Systeme de transfection pour transferer des acides nucleiques dans des cellules Ceased WO1999019502A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10290/99A AU1029099A (en) 1997-10-10 1998-10-02 Transfection system for the transfer of nucleic acids into cells

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP97117574A EP0908521A1 (fr) 1997-10-10 1997-10-10 Système de transfection pour le transfert d'ADN dans des cellules
EP97117574.0 1997-10-10
EP97119050.9 1997-11-03
EP97119050 1997-11-03
EP98111001.8 1998-06-16
EP98111001A EP0967288A1 (fr) 1998-06-16 1998-06-16 Système pour la transfection génique de celules

Publications (1)

Publication Number Publication Date
WO1999019502A1 true WO1999019502A1 (fr) 1999-04-22

Family

ID=27238300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/006273 Ceased WO1999019502A1 (fr) 1997-10-10 1998-10-02 Systeme de transfection pour transferer des acides nucleiques dans des cellules

Country Status (2)

Country Link
AU (1) AU1029099A (fr)
WO (1) WO1999019502A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180984A1 (fr) * 2016-04-14 2017-10-19 The Texas A&M University System Biomarqueurs épigénétiques et à micro-arn de premier trimestre pour la prééclampsie
RU2637371C2 (ru) * 2015-11-17 2017-12-04 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Гистоны и биодеградируемые липиды как средство для доставки нуклеиновых кислот в клетки эукариот
CN112166196A (zh) * 2018-05-18 2021-01-01 豪夫迈·罗氏有限公司 大核酸的靶向细胞内递送
EP3877526A4 (fr) * 2018-11-08 2023-03-29 Summation Bio, Inc. Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques
EP4136235A4 (fr) * 2020-04-13 2024-10-16 Summation Bio, Inc. Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD256148A1 (de) * 1986-09-21 1988-04-27 Akad Wissenschaften Ddr Verpackungsverfahren von dna zum gentransfer in tierische zellen
US5411956A (en) * 1989-12-25 1995-05-02 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
DE4418965A1 (de) * 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
WO1995034647A1 (fr) * 1994-06-13 1995-12-21 Vanderbilt University Compositions et procedes d'amelioration de l'apport d'acides nucleiques a des cellules
WO1996014424A1 (fr) * 1994-11-08 1996-05-17 Medical Research Council Methode de transfert d'adn
WO1996020732A2 (fr) * 1994-12-30 1996-07-11 Chiron Corporation Administration atraumatique de vehicules d'apport de genes
DE19616645A1 (de) * 1996-04-26 1997-10-30 Max Delbrueck Centrum Verfahren zum Gentransfer in tierische Zellen

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD256148A1 (de) * 1986-09-21 1988-04-27 Akad Wissenschaften Ddr Verpackungsverfahren von dna zum gentransfer in tierische zellen
US5411956A (en) * 1989-12-25 1995-05-02 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
DE4418965A1 (de) * 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
WO1995034647A1 (fr) * 1994-06-13 1995-12-21 Vanderbilt University Compositions et procedes d'amelioration de l'apport d'acides nucleiques a des cellules
WO1996014424A1 (fr) * 1994-11-08 1996-05-17 Medical Research Council Methode de transfert d'adn
WO1996020732A2 (fr) * 1994-12-30 1996-07-11 Chiron Corporation Administration atraumatique de vehicules d'apport de genes
DE19616645A1 (de) * 1996-04-26 1997-10-30 Max Delbrueck Centrum Verfahren zum Gentransfer in tierische Zellen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BOULIKAS T. AND MARTIN F.: "Histones, protamine, and polylysine but not poly(E:K) enhance transfection efficiency.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 10, no. 2, February 1997 (1997-02-01), pages 317 - 322, XP002058322 *
FELGNER P. L.: "PARTICULATE SYSTEMS AND POLYMERS FOR IN VITRO AND IN VIVO DELIVERY OF POLYNUCLEOTIDES", ADVANCED DRUG DELIVERY REVIEWS, vol. 5, no. 3, September 1990 (1990-09-01), pages 163 - 187, XP000603153 *
FRITZ J. D. ET AL.: "Gene transfer into mammalian cells using histone-condensed plasmid DNA.", HUMAN GENE THERAPY, vol. 7, 1 August 1996 (1996-08-01), pages 1395 - 1404, XP002058321 *
WAGNER E. ET AL.: "Transferrin-polycation-DNA complexes: The effect of polycations on the structure of the complex and DNA delivery to cells.", PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4255 - 4259, XP002058323 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2637371C2 (ru) * 2015-11-17 2017-12-04 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Гистоны и биодеградируемые липиды как средство для доставки нуклеиновых кислот в клетки эукариот
WO2017180984A1 (fr) * 2016-04-14 2017-10-19 The Texas A&M University System Biomarqueurs épigénétiques et à micro-arn de premier trimestre pour la prééclampsie
US11344121B2 (en) 2016-04-14 2022-05-31 The Texas A&M University System Methods of predicting preeclampsia using biomarkers
CN112166196A (zh) * 2018-05-18 2021-01-01 豪夫迈·罗氏有限公司 大核酸的靶向细胞内递送
EP3877526A4 (fr) * 2018-11-08 2023-03-29 Summation Bio, Inc. Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques
US12428445B2 (en) 2018-11-08 2025-09-30 Adarsha Koirala Mini-nucleosome core proteins and use in nucleic acid delivery
EP4136235A4 (fr) * 2020-04-13 2024-10-16 Summation Bio, Inc. Proétéines de noyau de mini-nucléosomes et leur utilisation dans l'administration d'acides nucléiques

Also Published As

Publication number Publication date
AU1029099A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
AU2022200130B2 (en) Engineered Cas9 systems for eukaryotic genome modification
Perales et al. An evaluation of receptor‐mediated gene transfer using synthetic DNA‐ligand complexes
JP3683798B2 (ja) 脊椎動物における外因性ポリヌクレオチド配列の発現
AU781356B2 (en) Viral core protein-cationic lipid-nucleic acid-delivery complexes
US5843643A (en) Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid
KR20220044811A (ko) Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기
US20240417429A1 (en) Compositions and methods for skipping exon 45 in duchenne muscular dystrophy
US7981676B2 (en) Method for transfer of molecular substances with prokaryotic nucleic acid-binding proteins
KR20210027389A (ko) 공여자 폴리뉴클레오티드의 삽입에 의한 게놈 편집을 위한 조성물 및 방법
JP2009232862A (ja) 治療および診断に使用する新規な特性をもたらしおよび／または該特性を現す組成物
Zhai et al. SV40 large T antigen binds to the TBP-TAF (I) complex SL1 and coactivates ribosomal RNA transcription.
CA2241923C (fr) Systeme de transfert de genes par l'intermediaire de recepteurs pour therapie genique ciblee de tumeurs
EP1470226B1 (fr) Regulation de l'expression genique au moyen d'un complexe constitue d'un oligonucleotide et d'un peptide regulateur
JP2002316997A (ja) 目的とするアニオン性物質を細胞に導入するための複合体
NZ521564A (en) Compositions for drug delivery
KR20030062788A (ko) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
EP4522221A1 (fr) Compositions et procédés d'administration d'agents thérapeutiques à base d'acides nucléiques
WO1999019502A1 (fr) Systeme de transfection pour transferer des acides nucleiques dans des cellules
US6800483B1 (en) Compositions and methods for sensitizing and inhibiting growth of human tumor cells
KR20030062789A (ko) 생체분자 전달 펩타이드 ｓｉｍ2-ｂｔｍ 및 이것을포함하는 생명공학제품
EP0967288A1 (fr) Système pour la transfection génique de celules
Cao et al. Intracellular localization and sustained prodrug cell killing activity of TAT-HSVTK fusion protein in hepatocelullar carcinoma cells
EP0908521A1 (fr) Système de transfection pour le transfert d'ADN dans des cellules
CN115484815A (zh) 用于在大豆中表达rna指导的核酸酶和dna结合蛋白的改进多核苷酸
CA2481399A1 (fr) Peptides, compositions pharmaceutiques contenant ces peptides pour le traitement du cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA